Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose simvastatin for secondary progressive multiple sclerosis
2017-003008-30Phase 2Unknown
- Sponsor
- University College London
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Simvastatin with Placebo (2 arms). Primary endpoint: Effect of simvastatin on cerebral blood flow. Status: unknown.
02
Drugs
simvastatin
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2017-003008-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003008-30.